Navigation Links
ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
Date:5/19/2010

LOS ANGELES, May 19 /PRNewswire/ -- ImaginAb, Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group of Companies) have concluded two research collaboration agreements around a clinical therapeutic antibody asset currently under development by GSK in the field of oncology.

"ImaginAb is pleased to have formalized this collaboration with the GSK CIC," said Dr. Christian Behrenbruch, CEO of ImaginAb. "Not only does GSK have an excellent biologics pipeline, but the company's large-scale commitment to diagnostic imaging is extremely impressive and this particular collaboration is a natural fit with ImaginAb's technology platform."

"Our collaboration with ImaginAb for antibody fragment imaging is part of our further exploration of the role of biologics in diagnostic imaging with Positron Emission Tomography (PET), an increasingly important clinical modality and a tool that is of significant interest to pharma in the discovery and development of new therapeutics," commented Dr. Paul Matthews, VP for Translational Research and Head of the GSK CIC. "As we expand and develop our pipeline, technologies such as ImaginAb's recombinant antibody fragment engineering technology may help us to look at targeted molecular therapeutics in new ways."

About GSK Clinical Imaging Centre

GlaxoSmithKline (GSK), Imperial College London (ICL) and the Medical Research Centre (MRC) have established a unique research collaboration in medical imaging, creating a Clinical Imaging Centre (CIC) based at Hammersmith Hospital in West London. The GSK CIC uses and advances the latest technologies in magnetic resonance imaging (MRI) and positron emission tomography (PET). R
'/>"/>

SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
2. North Carolina GlaxoSmithKline Foundation Working With Nonprofits to Promote Health, Science and Education Through Ribbon of Hope Grants
3. Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
4. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
5. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
6. GlaxoSmithKline 14th Annual IMPACT Awards Seek Greater Philadelphia and Camden Healthcare Nonprofits
7. GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment
8. Federal Judge Rejects GlaxoSmithKlines Claims of Privilege
9. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
10. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
11. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)...  Today, the National Patient Advocate Foundation acknowledges that ... Representatives recently approved a bill that would prohibit insurers ... out-of-pocket fees for newer, more expensive oral anti-cancer drugs ... severe side-effects. However, the bill was amended to include ... to be a barrier to patients with cancer and ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... 15, 2007 - Gemin X Biotechnologies,Inc. announced today ... that its lead compound, obatoclax (GX15-070), induced,cell death ... lines and,primary cells from 11 MCL patients. Obatoclax ... all relevant members of,the Bcl-2 protein family, a ...
... Showed Bioequivalence , LONDON, UK and ATLANTA, US, ... Sciele Pharma. Inc. (NASDAQ:SCRX) today,announce the successful completion ... of Sular, a calcium ,channel blocking agent for ... showed that the new Sular formulation is,bioequivalent to ...
Cached Medicine Technology:Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3
(Date:5/19/2013)... 2013 Actos lawsuit claims ... underway in U.S. District Court, Western District of Louisiana. ... 3rd, the Court has modified the litigation’s Bellwether Nomination ... rather than four. The next Status Conference in the ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/19/2013)... 2013 6Webs.com is the leader in ... who are considering an alarm system can do a ... leading security system providers online at 6Webs.com. Just recently ... DIY home security system companies, 6Webs.com currently is ... of home security companies before ranking the home security ...
(Date:5/19/2013)... Amenia, NY (PRWEB) May 19, 2013 ... According to the newest American Veterinary Medical Association ... two-thirds of American dog owners consider their dog a ... owners who had said as much five years earlier. ... total dollar value of the national income dedicated to ...
(Date:5/19/2013)... 19, 2013 Yeast infections are common in ... sensitive areas of the human body. A new yeast infection ... formula provides a unique method of application to help eliminate ... is now provided to men and women searching for a ... in the body through food and is stored in the ...
(Date:5/19/2013)... 2013 Buenos Aires, Argentina: Yoga classes ( ... Buenos Aires, Argentina by the Sivananda Yoga Vedanta ... 2372 - (Barrio Norte). Classes are 90 minutes and ... are offered in a calm environment, allowing visitors to ... healthy vegetarian food, among others. , The Yoga classes ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2
... ... Aging Month, an annual observance designed to raise awareness on the positive aspects of ... of the nation,s largest not-for-profit aging services organizations, offer the following simple and effective ... ...
... , Proposed law would regulate teens, right to ... the military , , WASHINGTON, Aug. 18 ... Suffolk teens under the age of 18 from using a sun-bed. ... the following statement regarding the bill: , , It ...
... , , EMERYVILLE, Calif., ... company, announced today that it has closed a $40 million Series ... Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also ... company announced the election of George M. Rehm, Managing Partner of ...
... New data show nanotechnology-related activities in every ... Aug. 18 Every state can now lay claim to the ... by the Project on Emerging Nanotechnologies (PEN) highlights more than 1,200 ... states and in the District of Columbia that are involved in ...
... cardiovascular complications , TUESDAY, Aug. 18 (HealthDay News) ... snoring, interrupted breathing and sleep disruption -- nearly double ... middle-aged and elderly men, according to major new research. ... an increased death risk, as much as 17 percent, ...
... , SCHAUMBURG, Ill., Aug. 18 The ... Motor o la, Inc. (NYSE: MOT ... Vulnerability Assessment solution , a patented wireless security technology aimed at proactively ... new method to secure wi r eless networks ...
Cached Medicine News:Health News:7 Easy Tips for Healthy Aging 2Health News:Indoor Tanning Association Opposes Suffolk Bill Banning Teens From Sun-Beds 2Health News:Adamas Pharmaceuticals Raises $40 Million in Series D Financing 2Health News:Adamas Pharmaceuticals Raises $40 Million in Series D Financing 3Health News:Putting Nanotechnology on the Map 2Health News:Putting Nanotechnology on the Map 3Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 2Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 3Health News:Sleep Apnea Raises Risk of Death, Especially for Men: Report 4Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 2Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 3Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 4Health News:Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing 5
Magnetic Farnsworth D15 kit Magnets move the color disks. Protects disks from fingerprints. Keeps all the disks in one place. Clear glass insures accurate color perception. Makes color testing fun....
... panel D15 test evaluation has a ... arrange caps with automatic creation 'horse-shoe' ... color deficiency analysis, calculation of color ... CCI, eye selection (OD, OS, OU) ...
... kit consists of a Matching Card, three HRR ... help prepare a child for subsequent HRR 4th ... use the test. For the youngest patients, the ... child learn the concept of matching and become ...
Spanish HRR/Amsler combination with Spanish and English directions for both HRR and amsler tests plus occluding glasses....
Medicine Products: